Podcast
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
Author(s):
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Amy Krambeck, MD, on considerations for building clinical programs in endourology
David Stanley, MD, on current trends in the management of kidney stones
Margaret Knoedler, MD, on robot-assisted mini-PCNL with the MONARCH Platform
Khurshid Ghani, MBChB, MS, FRCS, on current barriers to stent omission
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Related Content
